Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non‐Hodgkin's lymphomas of diffuse histology
暂无分享,去创建一个
E. Henderson | M. Barcos | T. Han | G. Gomez
[1] J. Farndon,et al. EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.
[2] R. Fisher,et al. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. , 1986, Annals of internal medicine.
[3] H. Silberman,et al. Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M Coleman,et al. Chemotherapy for large-cell lymphoma: optimism and caution. , 1985, Annals of internal medicine.
[5] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[6] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[7] J. Armitage,et al. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) , 1982, Cancer.
[8] E. Henderson,et al. Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas. , 1982, Cancer treatment reports.
[9] R. Fisher,et al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981, Blood.
[10] D. Green,et al. COMPARISON OF THREE METHODS OF CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKÆMIA , 1980, The Lancet.
[11] J. Ultmann,et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. , 1980, Annals of internal medicine.
[12] C. Coltman,et al. Superiority of adriamycin‐containing combination chemotherapy in the treatment of diffuse lymphoma. A southwest oncology group study , 1979, Cancer.
[13] G. Gomez,et al. Cell cycle agents and cyclophosphamide in the treatment of diffuse histiocytic lymphoma. , 1978, European journal of cancer.
[14] T. Chu,et al. Xanthine nephropathy during chemotherapy in deficiency of hypoxanthine-guanine phosphoribosyltransferase. , 1978, Archives of internal medicine.
[15] M. Pasmantier,et al. High dose methotrexate with citrovorum factor in adult resistant lymphoma , 1977, Cancer.
[16] D. Rosenthal,et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. , 1977, Blood.
[17] K. Shimaoka,et al. Multiple agent chemotherapy for advanced histiocytic lymphoma. , 1976, European journal of cancer.
[18] W. Shapiro,et al. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.
[19] J. Bertino,et al. Long‐term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy , 1975, Cancer.
[20] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[21] W. Vogler,et al. TOXICITY AND ANTITUMOR EFFECT OF DIVIDED DOSES OF METHOTREXATE. , 1965, Archives of internal medicine.
[22] D. Rall,et al. Clinical studies of dichloromethotrexate (NSC 29630) , 1965, Clinical pharmacology and therapeutics.